Analysis of Risk Factors for Revitrectomy in Eyes with Diabetic Vitreous Hemorrhage.

fibrinogen proliferative diabetic retinopathy retinal ischemia revitrectomy vitreous hemorrhage

Journal

Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585

Informations de publication

Date de publication:
2023
Historique:
received: 13 07 2023
accepted: 14 09 2023
medline: 27 9 2023
pubmed: 27 9 2023
entrez: 27 9 2023
Statut: epublish

Résumé

We aimed to investigate the risk factors associated with revitrectomy in eyes with diabetic vitreous hemorrhage and to determine the prognosis of these patients at least one year postoperatively. This retrospective case-control study had a minimum follow-up period of one year. Patients were divided into single vitrectomy group (control group, n=202) and revitrectomy group (case group, n=36) for analysis. The indications, number, and timing of revitrectomies were documented. And the revitrectomy group was further divided into two vitrectomies group (n=30) and three or more vitrectomies group (n=6). The best-corrected visual acuity (BCVA) at the last follow-up and the occurrence of neovascular glaucoma (NVG) were compared among the single vitrectomy, two vitrectomies and three or more vitrectomies groups. We conducted a thorough collection of patient data and used univariate and binary logistic regression analyses to identify the risk factors associated with revitrectomy. A total of 197 patients (238 eyes) were included. Thirty-six eyes (15.1%) required revitrectomy with six eyes (2.5%) undergoing three or more vitrectomies during the follow-up period. The median duration of the second vitrectomy was 3 (2-6) months. The indications for a second vitrectomy included 28 eyes (77.8%) of postoperative vitreous hemorrhage and 7 eyes (22.2%) combined with tractional retinal detachment. Patients undergoing three or more vitrectomies had significantly worse postoperative BCVA and a higher incidence of NVG ( Patients requiring revitrectomy tended to have higher fibrinogen levels, tightly adhered fibrovascular membranes, higher HbA1c levels, and worse prognoses.

Identifiants

pubmed: 37753483
doi: 10.2147/DMSO.S429938
pii: 429938
pmc: PMC10518247
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2865-2874

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023 Guo et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Acta Ophthalmol. 2014 Sep;92(6):571-6
pubmed: 24373516
Am J Ophthalmol. 1985 Nov 15;100(5):637-43
pubmed: 2414993
Eye (Lond). 2012 Apr;26(4):576-82
pubmed: 22241020
BMC Ophthalmol. 2020 Jul 16;20(1):292
pubmed: 32677996
Retina. 2015 Oct;35(10):1931-42
pubmed: 26398553
Jpn J Ophthalmol. 2015 Sep;59(5):288-94
pubmed: 26202442
Am J Ophthalmol. 1987 Dec 15;104(6):607-13
pubmed: 2446501
Blood. 2019 Feb 7;133(6):511-520
pubmed: 30523120
Cochrane Database Syst Rev. 2015 Aug 07;(8):CD008214
pubmed: 26250103
Clin Ophthalmol. 2020 Jun 10;14:1559-1563
pubmed: 32606570
Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56
pubmed: 18201511
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Diabetes Care. 2013 Aug;36 Suppl 2:S272-5
pubmed: 23882058
Front Cell Infect Microbiol. 2021 Aug 03;11:734005
pubmed: 34414135
PLoS One. 2021 Jan 14;16(1):e0244281
pubmed: 33444332
Int J Med Sci. 2021 Jan 26;18(6):1390-1398
pubmed: 33628095
Ophthalmology. 2002 Oct;109(10):1814-20
pubmed: 12359600
Invest Ophthalmol Vis Sci. 2012 Sep 21;53(10):6403-10
pubmed: 22899753
Acta Ophthalmol. 2020 Jun;98(4):e434-e439
pubmed: 31674137
J Diabetes Complications. 2020 Sep;34(9):107641
pubmed: 32605862
Br J Ophthalmol. 2018 Aug;102(8):1077-1085
pubmed: 29246890
Retina. 2010 Nov-Dec;30(10):1671-7
pubmed: 21060273
Ophthalmology. 2000 Sep;107(9):1729-36
pubmed: 10964837
J Diabetes Investig. 2018 Jul;9(4):940-945
pubmed: 29265703
Diabetes Metab Syndr Obes. 2021 Jun 02;14:2483-2488
pubmed: 34103957
Acta Ophthalmol. 2021 Feb;99(1):83-89
pubmed: 32643273
Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):665-671
pubmed: 27770210
J Clin Med. 2023 Apr 20;12(8):
pubmed: 37109325
Retina. 2022 Jun 1;42(6):1103-1110
pubmed: 35594076
Am J Ophthalmol. 2013 Apr;155(4):757-63, 763.e1-2
pubmed: 23317651
Br J Ophthalmol. 2004 Aug;88(8):1064-8
pubmed: 15258026
Arch Ophthalmol. 1992 Apr;110(4):506-10
pubmed: 1562258
J Intern Med. 2012 Mar;271(3):227-36
pubmed: 22333004
Am J Ophthalmol. 1987 Dec 15;104(6):614-8
pubmed: 2446502
BMC Ophthalmol. 2023 May 15;23(1):215
pubmed: 37189104
Mediators Inflamm. 2013;2013:818671
pubmed: 24363502
Curr Eye Res. 2010 Apr;35(4):308-13
pubmed: 20373898
Clin Ophthalmol. 2010 Sep 20;4:1043-6
pubmed: 20922040
Diabetes Care. 2015 Aug;38(8):1610-4
pubmed: 26207054
Comput Biol Med. 2021 Aug;135:104599
pubmed: 34247130
Diabetes Metab Syndr Obes. 2023 Jun 23;16:1859-1867
pubmed: 37384130

Auteurs

Haoxin Guo (H)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Wenbo Li (W)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Kuan Wang (K)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.
Cangzhou Eye Hospital, Cangzhou, People's Republic of China.

Zetong Nie (Z)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Xiang Zhang (X)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Siqiong Bai (S)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Naxin Duan (N)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Xiaorong Li (X)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Bojie Hu (B)

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin University Eye Hospital, Tianjin, People's Republic of China.

Classifications MeSH